Antigenic targets for renal cell carcinoma immunotherapy
Antigenic targets for renal cell carcinoma immunotherapy
复制标题
DOI：
10.1517/14712598.4.11.1791
复制
发表时间：
2004-11
影响因子：
4.6
通讯作者：
J. Vieweg;A. Jackson
中科院分区：
文献类型：
--
作者：
J. Vieweg;A. Jackson
肾细胞癌（RCC）已被证明对免疫干预有反应，因此对利用免疫系统识别和根除肾脏恶性肿瘤的能力产生了持续的兴趣。肿瘤相关抗原的表征取得了相当大的进展，加上树突状细胞作为免疫和耐受的主要调节因子的认识，为人类癌症的免疫干预开辟了新的可能性。然而，与其他肿瘤系统相比，RCC表达的临床相关抗原尚未被鉴定。因此，大多数RCC疫苗试验采用了来自肿瘤细胞的未分级抗原，目的是引发针对肿瘤表达的许多未知抗原的T细胞应答。最近发现的在肿瘤发生中具有关键作用的基因促进了新的、更通用的靶点的鉴定，这些靶点可能使癌症疫苗更实用、更适用、更有效。此外，针对肿瘤抗原的免疫可以与肿瘤基质相关靶标组合，从而发挥协同抗肿瘤作用。继续鉴定分子靶点，配合更有效的疫苗接种方案，可能会产生具有临床影响的疫苗接种策略。
Renal cell carcinoma (RCC) has been shown to respond to immunotherapeutic intervention, thus fostering continued interest in exploiting the ability of the immune system to recognise and eradicate renal malignancy. Considerable progress in the characterisation of tumour-associated antigens, coupled with the appreciation that dendritic cells act as master regulators of immunity and tolerance, has opened new possibilities for immunotherapeutic intervention against human cancer. However, in contrast to other tumour systems, clinically relevant antigens expressed by RCC have not yet been identified. Therefore, most RCC vaccine trials have employed unfractionated antigens derived from tumour cells, with the goal of eliciting T cell responses against many unknown antigens expressed by the tumour. The recent discovery of genes with critical roles in oncogenesis has facilitated the identification of novel, more universal targets that may make cancer vaccines more practical, applicable and, potentially, more effective. In addition, immunisation against tumour antigens can be combined with tumour stroma-associated targets, thereby exerting a synergistic antitumour effect. Continued identification of molecular targets, in concert with more effective vaccination protocols, is likely to produce vaccination strategies with clinical impact.